250 related articles for article (PubMed ID: 36905319)
1. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
[TBL] [Abstract][Full Text] [Related]
2. Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis.
Abbasi B; Shaw NM; Lui JL; Hakam N; Nabavizadeh B; Breyer BN
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5721. PubMed ID: 37909414
[TBL] [Abstract][Full Text] [Related]
3. Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy.
Furtado TP; Miranda EP; Deveci S; Jenkins L; Narus J; Nelson C; Mulhall JP
J Sex Med; 2023 Dec; 21(1):29-32. PubMed ID: 37973393
[TBL] [Abstract][Full Text] [Related]
4. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
6. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
7. Clinical monograph for drug formulary review: erectile dysfunction agents.
Campbell HE
J Manag Care Pharm; 2005 Mar; 11(2):151-71. PubMed ID: 15766322
[TBL] [Abstract][Full Text] [Related]
8. Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis.
Shin YE; Rojanasarot S; Hincapie AL; Guo JJ
Sex Med; 2023 Oct; 11(5):qfad059. PubMed ID: 38034088
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
11. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
Lowe G; Costabile RA
J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666
[TBL] [Abstract][Full Text] [Related]
12. Major adverse cardiovascular events related to phosphodiesterase 5 inhibitors: analysis of real-life data from Eudra-Vigilance database.
DE Nunzio C; Nacchia A; Grimaldi MC; Turchi B; Rovesti L; Franco A; Guarnotta G; Voglino O; Mancini E; Baldassarri V; Lombardo R; Cicione A; Tubaro A
Minerva Urol Nephrol; 2024 Apr; 76(2):203-209. PubMed ID: 38498298
[TBL] [Abstract][Full Text] [Related]
13. Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight.
Mostafa T; Alghobary MF
Sex Med Rev; 2022 Jul; 10(3):392-402. PubMed ID: 34903486
[TBL] [Abstract][Full Text] [Related]
14. Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?
Rezaee ME; Gross MS
J Sex Med; 2020 Aug; 17(8):1579-1582. PubMed ID: 32622767
[TBL] [Abstract][Full Text] [Related]
15. An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.
Bai WJ; Li HJ; Dai YT; He XY; Huang YR; Liu JH; Sorsaburu S; Ji C; Jin JJ; Wang XF
Asian J Androl; 2015; 17(1):61-7. PubMed ID: 25370206
[TBL] [Abstract][Full Text] [Related]
16. Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Khouri C; Lepelley M; Roustit M; Montastruc F; Humbert M; Cracowski JL
Chest; 2018 Jul; 154(1):136-147. PubMed ID: 29275134
[TBL] [Abstract][Full Text] [Related]
17. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
18. A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil.
Wang Y; Zhao B; Yang H; Wan Z
Andrology; 2024 May; 12(4):785-792. PubMed ID: 37724699
[TBL] [Abstract][Full Text] [Related]
19. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
[TBL] [Abstract][Full Text] [Related]
20. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
